The C$250 billion ($186 billion) Ontario Teachers’ Pension Plan in Toronto has partnered with Chicago firm Linden Capital Partners to create a new investment platform focused on advancing clinical research.
The initiative will be led by Dr. John Potthoff, who is currently the chair of Elligo Health Research and bring with him three decades of experience leading development in both drugs and devices. The partnership will invest in companies and technology that are fostering connections and collaborations among patients, research sites, pharmaceutical companies and the broader clinical research community.
“We believe our collaboration is a potential game-changer for clinical research. We see a significant gap in the industry and believe this strategic alliance will drive meaningful change and opportunity,” said Dr. Potthoff. “Recognizing the unique needs of each therapeutic and scientific area, we aim to streamline processes, enhance efficiencies, and foster collaborations that benefit all stakeholders, especially patients.”
The size of the joint venture was not disclosed. Through strategic M&A and the deployment of technology, the initiative will seek to enhance collaboration across all aspects of clinical research, from patient engagement through regulatory submissions, ensuring that every phase of the research process is seamlessly connected and optimized.
Linden Operating Partner Margaret Keegan will be chairing the partnership. She has held executive roles within clinical development at large pharmaceutical and CRO companies, including PPD, IQVI and PRA Health Sciences. She is also the former chair of the Board for Clinical Data Interchange Standards Consortium, in addition to serving as CEO of RQM, a provider of regulatory, clinical and quality solutions to the medtech industry.
Founded in 2004, Linden claims to be the largest dedicated healthcare private equity firm in the U.S. based on total capital raised after having invested in over 40 companies via more than 325 transactions. The $8 billion firm is focused on middle market companies in the medical products, specialty distribution, pharmaceutical and services segments of healthcare.
“We recognize the inefficiencies and shortcomings of clinical research services that impact patients, research sites, sponsors, and regulators, leading to delays in getting critical therapies to patients in need,” Keegan said. “Our commitment is to address these challenges head-on and catalyze positive change in our industry.”